GO
Loading...

Pharmaceuticals

More

  • NEW YORK, Nov 9- Now that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential market that could rival the success of statins, which generated more than $30 billion a year in sales at their peak. Several companies are working on...

  • BOSTON, Nov 6- Herbalife Ltd.' s new compliance chief has been on the job for exactly one month and on Thursday the supplements and weight loss company's biggest detractor, billionaire investor William Ackman, gave her pointers on how she might proceed. Herbalife's Nutrition Clubs' training programs, its compensation statements, income claims, sales of...

  • NEW YORK, Nov 6- Investors and bankers have been lamenting the potential death of large cross-border healthcare mergers since the U.S. Treasury Department announced in late September that it would curtail the tax breaks from international deals designed to give U.S. companies a legal home in a low-tax country. Now many bankers and investors expect companies...

  • Nov 6- Hospira Inc reported a quarterly profit that handily beat analysts' estimates as the company raised prices and sold more of its injectable drugs. Hospira's shares rose as much as 9.2 percent to a more than three-year high of $57.99 on Thursday. Hospira challenged the decision but lost the case.

  • *FDA says not enough "verifiable" data, asks for fresh trial. *FDA says drug could have led to a cardiac event in trial. Nov 6- Canada's Aeterna Zentaris Inc said the U.S. Food and Drug Administration rejected macimorelin, which the drugmaker had hoped would be the first orally administered drug to determine if adults had growth hormone deficiency.

  • US pulls approval for these Nexium, Valcyte generics Thursday, 6 Nov 2014 | 9:47 AM ET

    The U.S. FDA has revoked a tentative approval for India's Ranbaxy to make a cheap copy of AstraZeneca's heartburn drug Nexium.

  • *Ranbaxy says FDA revoked approval for copies of Nexium, Valcyte. *FDA said approvals were given "in error"- Ranbaxy. The FDA has also stripped Ranbaxy of tentative approval and six-month exclusivity for a copy of Roche Holding AG's antiviral Valcyte, a fresh blow to the Indian company that has been hit by a raft of regulatory bans over poor production quality.

  • LONDON, Nov 6- The Europe Union and drugmakers pledged on Thursday to invest 280 million euros in Ebola research, with the lion's share going to the testing and manufacture of potential vaccines. The funding will go to projects backed by the Innovative Medicines Initiative, a public-private scheme jointly paid for by the European Commission and the...

  • LONDON, Nov 6- The Europe Union and drugmakers pledged on Thursday to invest 280 million euros into Ebola research, with the lion's share going to fast-track the testing and manufacture of potential vaccines. The funding will go to projects backed by the Innovative Medicines Initiative, a public-private scheme jointly paid for by the European Commission and...

  • LONDON, Nov 6- AstraZeneca raised its 2014 sales forecast for the second quarter in a row on Thursday, as the delayed arrival of generic copies of its Nexium drug in the United States kept cash flowing from the heartburn and ulcer pill. Britain's second biggest drugmaker, which saw off a $118 billion takeover bid from Pfizer in May, now expects revenue to grow in low...

  • LONDON, Nov 6- AstraZeneca raised its 2014 sales forecast for the second quarter in a row on Thursday, as the delayed arrival of Nexium generics in the United States kept cash flowing from the heartburn and ulcer pill. Britain's second biggest drugmaker, which saw off a $118 billion takeover approach from Pfizer in May, now expects revenue to grow slightly this...

  • LONDON, Nov 6- AstraZeneca raised its 2014 sales forecast for the second quarter in a row on Thursday, as the delayed arrival of Nexium generics in the United States kept cash flowing from the heartburn and ulcer pill. Britain's second biggest drugmaker, which saw off a $118 billion takeover approach from Pfizer in May, now expects revenue this year to grow in low...

  • In September life-science company Calico, which was set up by Google last year to investigate the ageing process, joined with U.S. drugmaker AbbVie in committing an initial $250 million apiece to developing cures for age-related diseases. Away from the limelight, however, Switzerland's Novartis and Denmark's Novo Nordisk are already testing new roles for...

  • CNBC's Meg Tirrell speaks to Alex Gorsky, Johnson & Johnson chairman & CEO, about helping military veterans transition from the battlefield into corporate America.

  • Nov 5- The top executive of Actavis Inc, which sources say is pursuing a "white knight" acquisition of Allergan Inc, made a case Wednesday for doing a deal, saying the drug company could continue to grow earnings and manage its debt load. "If there was an opportunity, I think we've demonstrated as a team that if it was the right strategic opportunity with strong...

  • Nov 5- Endo International Plc raised its 2014 forecast for the third time and reported a better-than-expected quarterly profit, its recent acquisitions helping boost generic drug sales in the United States by nearly 74 percent. The Dublin- based maker of drugs and medical devices, which last month clinched a deal to buy Auxilium Pharmaceuticals Inc, raised its...

  • Nov 5- Endo International Plc, which is acquiring Auxilium Pharmaceuticals Inc, reported a better-than-expected quarterly profit due to a nearly 74 percent jump in sales of its generic drugs in the United States. The Dublin- based company's adjusted net income rose to $182.3 million in the quarter ended Sept. 30, from $160.7 million a year earlier.

  • Nov 5- Drugmaker Actavis Plc posted better-than-expected quarterly revenue and profit, helped by strong growth in its branded drug business in North America. The company, which also has a large generics business, posted a net loss of $1.04 billion, or $3.95 per share, in the third quarter ended Sept. 30, compared with a profit of $65.5 million, or 49 cents per share, a...

  • BEIJING, Nov 4- China has contributed over $120 million to fight the spread of the Ebola virus, but its billionaire tycoons- it has more than anywhere outside the United States- have, publicly at least, donated little to the cause, underscoring an immature culture of philanthropy in the world's second-biggest economy. Many big Chinese companies have invested in...

  • Nov 3- Laboratory Corp of America Holdings said it would pay $6.1 billion for Covance Inc, which carries out trials for drugmakers, as its diagnostic services business faces pressure from reimbursement cuts. Covance's shares jumped 25 percent to $100.28, nearing LabCorp's offer price of $105 per share. The cash-and-stock deal allows LabCorp to expand into the...